 But that's not happening right now because, for example, many studies which are concerned with psychedelic-assisted psychotherapy, be it MDMA, psilocybin, and so on, are largely recruiting folks with prior recreational experiences. That's perhaps good in a way, right? Because these folks know what's coming for them. Maybe they're most excited. They have positive experiences. But of course, in principle, this isn't the target population for an FDA approval, right?